AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00852579
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02462187
Drug: NVN1000 8% Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once and twice daily
Trial: NCT02462187
Drug: NVN1000 16%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT02462187
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator
Trial: NCT02462187
Drug: NVN1000 24%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT00728156
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: Hydroxy methyl cellulose, similar in weight to the active medication 75 mgs, oral tablets, once a day
Trial: NCT01323985
Drug: GSK2315698
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg-400mg IV (in the vein) single dose over 1-4 hours
Trial: NCT01323985
Drug: GSK2315698
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV (in the vein) single dose over 24 hours, in two sessions
Trial: NCT01861561
Drug: Low-dose intravenous cyclophosphamide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months, total 7 doses
Trial: NCT01861561
Drug: High-dose intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide every 4 weeks/months, total in 7 doses:~the 1st dose-500 mg/m2/dose,the 2nd dose-750 mg/m2/dose, the 3rd-7th doses- 1,000 mg/m2/dose with the maximum dose at 1,500 mg/dose
Trial: NCT03968302
Drug: ARM A Triple therapy for helicobacter pylori
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The triple regimen was defined as a combination of amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.
Trial: NCT03968302
Drug: ARM B Quadruple therapy for helicobacter pylori
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy included colloidal bismuth subcitrate 240 mg twice daily,amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.
Trial: NCT00194467
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo, once a day for 8 weeks
Trial: NCT02440204
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be administered according to their group in 1 minute to prevent remifentanil induced rigidity or complications.
Trial: NCT01142076
Drug: Xinju Xiaogao Prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment group
Trial: NCT01142076
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic dose of 10%
Trial: NCT03723798
Drug: SA001 Mid dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets b.i.d for 12 weeks
Trial: NCT03723798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets b.i.d for 12 weeks
Trial: NCT00347932
Drug: ISV-403
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with bacterial conjunctivitis were randomized to receive 0.6% ISV-403 eye drops three times a day (TID) for 5 days.
Trial: NCT00347932
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with bacterial conjunctivitis were randomized to receive vehicle eye drops three times a day (TID) for 5 days.
Trial: NCT03318354
Drug: Daiichi Sankyo Inc's Benicar Tablets 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02176850
Drug: Micardis®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04039412
Drug: Hybrid regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two-step (dual-quadruple) treatment
Trial: NCT04039412
Drug: Reverse hybrid regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one-step two-phase (quadruple-dual) treatment
Trial: NCT02197806
Drug: AGN-199201
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 to 2 drops of AGN-199201 ophthalmic solution in the eye(s) as per protocol.
Trial: NCT02197806
Drug: AGN-190584
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 to 2 drops of AGN-190584 ophthalmic solution in the eye(s) as per protocol.
Trial: NCT02197806
Drug: AGN-199201 Vehicle
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 to 2 drops of AGN-199201 vehicle in the eye(s) as per protocol.
Trial: NCT01420445
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three times daily / 7 days
Trial: NCT02046460
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid, 300mg o.p.d.
Trial: NCT02046460
Drug: Vitamin K antagonist
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K-antagonists, target INR 2.0-3.0
Trial: NCT00368654
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Initial dose 5 mg, then 15 mg per week
Trial: NCT03891420
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV infusion
Trial: NCT01946373
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01680718
Drug: Intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010).
Trial: NCT01581307
Drug: FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The usual treatment if gemcitabine chemotherapy has failed is chemotherapy with a drug combination called FOLFOX (folinic acid, 5-FU and oxaliplatin) given through a vein every 2 weeks for 6-10 cycles. Participants will receive this treatment.
Trial: NCT02368795
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin 100 mg suppository ten minutes before ERCP
Trial: NCT02368795
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Ringer's lactate serum with a dose of 6 cc/kg/h during the procedure and 20 cc/kg after ERCP as a bolus dose and 3 cc/kg/h for the next 8 hours.
Trial: NCT01754844
Drug: AZD7624
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose inhaled IMP via a nebulizer
Trial: NCT01754844
Drug: Placebo to match
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose inhaled Placebo via a nebulizer
Trial: NCT01831154
Drug: Standard Glycemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin was Regular Insulin administered intravenous bolus.
Trial: NCT00642239
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
Trial: NCT00768300
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match ambrisentan was administered orally once daily.
Trial: NCT02439905
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In normal saline group, normal saline infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
Trial: NCT03249311
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
Trial: NCT02439307
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 2 weeks
Trial: NCT04098302
Drug: Placebo Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules with matching appearance as Dutasteride Capsules
Trial: NCT03175341
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1,5 g ascorbic acid dissolved in 100 ml sterile water, and 0,75 g ascorbic acid dissolved in 100 ml sterile water.
Trial: NCT03175341
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml normal saline 0.9%
Trial: NCT03225248
Drug: UI05MSP015CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UI05MSP015CT and Placebo of Gasmotin
Trial: NCT01555489
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3x per week
Trial: NCT01460069
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo pens contain saline and are administered in the same way and volume as (liraglutide) Victoza. The placebo pens are specially prepared for this study and will be used in the study only.
Trial: NCT03326063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
Trial: NCT01989429
Drug: M518101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-week comparative treatment period ( twice daily application) followed by a maximum 8-week period to evaluate time to relapse
Trial: NCT04541485
Drug: DWRX2003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscularly injection at pre-defined injection sites
Trial: NCT04541485
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscularly injection at pre-defined injection sites
Trial: NCT02830919
Drug: Glucosamine and chondroitin sulfate combination (Eurofarma)
RxNorm normalized name: chondroitin sulfates / glucosamine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02830919
Drug: Glucosamine and chondroitin sulfate combination (Zodic)
RxNorm normalized name: chondroitin sulfates / glucosamine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01984047
Drug: GSK3050002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3050002 is a white to off-white lyophilized powder that will be reconstituted with sterile water for intravenous infusion. It is available in the concentrations of 0.1 milligram (mg)/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg.
Trial: NCT01984047
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains normal saline (0.9% sodium chloride) for intravenous infusion
Trial: NCT00222144
Drug: Gleevec and Taxotere
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gleevec 600 mg QD for 12 months Taxotere IV 30 mg/m2 on day 1, 8 and 15
Trial: NCT00989508
Drug: Placebo marked PEXSIG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
Trial: NCT04061109
Drug: Recombinant Human Coagulation FVIII
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
Trial: NCT02524561
Drug: CEE pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens 0.45 mg/day
Trial: NCT02524561
Drug: Estradiol patch
RxNorm normalized name: Estradiol Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Climara 50 mcg/day
Trial: NCT02099084
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching study drug, administered subcutaneously.
Trial: NCT02379195
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 60 mg/kg are administered i.v on day -7 and -6
Trial: NCT03894696
Drug: Direct Acting Antivirals
RxNorm normalized name: DIRECT ACTING ANTIVIRALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: follow up chronic HCV patients recieving DAAs to detect anxiety and depression
Trial: NCT03489044
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To up-titrate placebo to two tablets twice daily followed by maintenance on placebo two tablets twice daily for four weeks and then down-titrate to nil over four weeks
Trial: NCT02091635
Drug: Placebo (for Motilitone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
Trial: NCT02091635
Drug: Motilitone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
Trial: NCT00003631
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00996658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching linagliptin tablets once daily
Trial: NCT03888378
Drug: 0.3% Topical Minocycline Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction
Trial: NCT03888378
Drug: 1% Topical Minocycline Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction
Trial: NCT00907985
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo will be provided.
Trial: NCT00374296
Drug: MGCD0103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGCD0103 administered orally three-times per week
Trial: NCT05051241
Drug: GFH018
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen. Other dose regimens, eg 7d-on/7d-off will also be considered to be explored when the safety/tolerability is confirmed.
Trial: NCT00650663
Drug: Ezetimibe + Simvastatin
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets; ezetimibe 10 mg and simvastatin 20 mg once daily for 12 weeks
Trial: NCT00650663
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablet; simvastatin 20 mg once daily for 12 weeks
Trial: NCT04224922
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00973336
Drug: Calcium and vitamin D
RxNorm normalized name: Wellesse Calcium and Vitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg calcium per day 800 IE vitamin D per day
Trial: NCT00997984
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosed in the AM or PM
Trial: NCT01926444
Drug: GIC-1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIC-1001 oral tablet, white-coated, to be taken with water
Trial: NCT00821158
Drug: Antioxidant
RxNorm normalized name: ANTIOXIDANT GS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant iv bolus
Trial: NCT00821158
Drug: Anti-inflammatory drug
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory tablet
Trial: NCT00093262
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04430361
Drug: 5-HT3 receptor antagonist
RxNorm normalized name: 5-HT3 receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HT3 receptor antagonist 2.5mg/iv
Trial: NCT00135460
Drug: nucleoside analogue sparing HAART regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01279876
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3mg oral, daily, one hour before sleep
Trial: NCT01715363
Drug: Fluorouracile
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01724229
Drug: Kendall Body Wash & Shampoo; Moisture Barrier Cream; 2-in-1 Cleanser; Antifungal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01999686
Drug: DLBS3233
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01999686
Drug: Placebo DLBS3233
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo DLBS3233 has the same ingredients with DLBS3233 capsule, except that it does not contain the active substance (DLBS3233).
Trial: NCT02185053
Drug: CPC-201
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02544750
Drug: GWP42003-P
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Trial: NCT00705770
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with vehicle
Trial: NCT00429871
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 950 mg/m2 orally twice a day on days 1-14 every 3 weeks for 6 consecutive cycles
Trial: NCT01537471
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01393899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets twice daily
Trial: NCT01393899
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets twice daily
Trial: NCT02503085
Drug: Nurofen for Children®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02503085
Drug: Algifor Dolo Junior®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02538536
Drug: PBI4050
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01460706
Drug: [68Ga]DOTATOC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120MBq 68Ga-DOTATOC intravenously and PET/CT imaging. Performed once to a patient before the surgery.
Trial: NCT00886769
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was provided in individual 6 mL glass vials each containing 150 mg placebo powder matching canakinumab as a lyophilized cake. Each reconstitued vial provided 150mg of placebo per 1 mL.
Trial: NCT00498043
Drug: R-CHOP14 induction regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP14 induction regimen
Trial: NCT00498043
Drug: R-ACVBP14 induction regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-ACVBP14 induction regimen
Trial: NCT00673179
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-Surgery, Regimen 1: IV Over 15 Minutes on Day 1 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV on Day 1 of Weeks 16, 21, and 26; Pre-Surgery, Regimen 2: IV over 15 Minutes on Day 1 of Weeks 1, 4, and 7. Dose 90 mg/m\^2.
Trial: NCT00673179
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pre-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 4, 5, 9, and 10; Post-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 14, 15, 19, 20, 24, 25, 29, and 30; Post-Surgery, Regimen 2: IV Over 4 Hours on Day 1 of Weeks 14, 15, 20, 21, 26, 27, 32, 33, 38, and 39. Dose 12 gm/m\^2, max 20 gm over 4 hours.
Trial: NCT00673179
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pre- and Post-Surgery, Regimen 1: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours; Post-Surgery, Regimen 2: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours. Dose 10 mg IV, with 10 mg orally every 6 hours.
Trial: NCT00651755
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m\^2 By Vein On Day 1
Trial: NCT00651755
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m\^2 By Vein Over 48 Hours On Days 1-2
Trial: NCT00536172
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo distribution matches the active medication.
Trial: NCT01751776
Drug: Placebo matching BI 655064
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 655064 injected subcutaneous.
Trial: NCT00281684
Drug: SB705498 400 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB705498 400 mg
Trial: NCT00281684
Drug: SB705498 1000 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB705498 1000 mg
Trial: NCT00281684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00281684
Drug: Co-Codamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-Codamol